Teva Pharma (TEVA) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
RBC Capital Upgrades Teva Pharma (TEVA) to Outperform
November 3, 2014 8:09 AM ESTRBC Capital upgraded Teva Pharma (NYSE: TEVA) from Sector Perform to Outperform with a price target of $68.00.
For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.
Shares of Teva Pharma closed at $56.47 yesterday.
... MoreTeva Pharma (TEVA) Price Target Raised to $64 at Deutsche Bank
October 30, 2014 2:00 PM EDTDeutsche Bank maintained a Buy rating on Teva Pharma (NYSE: TEVA) and raised its price target to $64.00 (from $63.00). The change follows solid Q3 results.
Analyst Gregg Gilbert said, "We updated our model following TEVAs 3Q results, which were notable for significant... More
